サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1730964

視神経脊髄炎スペクトラムの世界市場レポート 2025年

Neuromyelitis Optica Spectrum Disorder Global Market Report 2025

出版日
ページ情報
英文 175 Pages
納期
2～10営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.08円
視神経脊髄炎スペクトラムの世界市場レポート 2025年
出版日: 2025年05月16日
発行: The Business Research Company
ページ情報: 英文 175 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

視神経脊髄炎スペクトラム市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR8.4％で35億2,000万米ドルに成長します。予測期間の成長は、認知度の向上と早期診断、ヘルスケア支出の増加、研究開発投資の増加、自己免疫疾患の有病率の増加、NMOSD治療薬の臨床試験の増加、個別化医療に対する需要の高まりが牽引するとみられます。予測期間の主な動向としては、精密医療の進展、連携・パートナーシップの増加、技術革新、研究におけるAIとビッグデータの統合、在宅治療へのシフトなどが挙げられます。

多発性硬化症（MS）の有病率の上昇は、視神経脊髄炎スペクトラム（NMOSD）市場の成長を促進すると予想されます。多発性硬化症は、中枢神経系を侵し、炎症、神経損傷、神経症状を引き起こす慢性の自己免疫疾患です。MSの有病率の増加は、診断技術の向上、環境要因、遺伝的素因に起因します。MRIなどの医療用画像診断の進歩により、より早期かつ正確な診断が可能となり、発見される症例の増加に寄与しています。MSの診断件数が増加するにつれ、神経学的自己免疫疾患に対する認識も高まり、診断方法の改善やNMOSDのような疾患に対する理解も深まっています。例えば、2024年5月、多発性硬化症トラストは、英国では年間約7,100人のMS患者が新たに発生し、毎週約135人が新たに診断されていると報告しています。したがって、MSの有病率の増加がNMOSD市場の成長に拍車をかけています。

NMOSD市場の企業は、治療効果を高め、患者の転帰を改善するために、長時間作用型補体阻害剤などの革新的な治療法の開発に注力しています。長時間作用型補体阻害剤は、補体系を長期間抑制し、NMOSDにおける炎症と神経損傷を予防するように設計されています。これらの治療は再発を抑え、長期的な疾患管理に貢献します。例えば、2024年3月、米国のバイオ医薬品会社アレクシオン・ファーマシューティカルズと英国の製薬会社アストラゼネカは、抗アクアポリン-4（AQP4）抗体陽性NMOSD（成人）の治療薬として、ULTOMIRIS（ravulizumab-cwvz）の承認を取得しました。ウルトミリスは、NMOSD治療薬として承認された最初で唯一の長時間作用型C5補体阻害薬です。今回の承認は、第III相試験であるCHAMPION-NMOSD試験において、プラセボと比較して73週間にわたり再発リスクを98.6％減少させ、試験中に新たな安全性に関する懸念は認められなかったことに基づいています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

  • 世界の視神経脊髄炎スペクトラムPESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
  • 最終用途産業の分析
  • 世界の視神経脊髄炎スペクトラム市場：成長率分析
  • 世界の視神経脊髄炎スペクトラム市場の実績：規模と成長、2019年～2024年
  • 世界の視神経脊髄炎スペクトラム市場の予測：規模と成長、2024年～2029年、2034年
  • 世界の視神経脊髄炎スペクトラム総アドレス可能市場（TAM）

第6章 市場セグメンテーション

  • 世界の視神経脊髄炎スペクトラム市場：タイプ別、実績と予測、2019年～2024年、2024年～2029年、2034年
  • 視神経脊髄炎スペクトラムアクアポリン4抗体
  • 視神経脊髄炎スペクトラムアクアポリン4抗体なし
  • 世界の視神経脊髄炎スペクトラム市場：診断別、実績と予測、2019年～2024年、2024年～2029年、2034年
  • 画像検査
  • 磁気共鳴画像法（MRI）
  • 血液検査
  • その他診断
  • 世界の視神経脊髄炎スペクトラム市場：治療タイプ別、実績と予測、2019年～2024年、2024年～2029年、2034年
  • C5タンパク質阻害剤
  • モノクローナル抗体
  • 血漿交換療法
  • コルチコステロイド
  • 免疫グロブリン療法
  • 薬
  • その他の治療の種類
  • 世界の視神経脊髄炎スペクトラム市場：流通チャネル別、実績と予測、2019年～2024年、2024年～2029年、2034年
  • 病院薬局
  • 小売薬局
  • オンライン薬局
  • 世界の視神経脊髄炎スペクトラム市場：エンドユーザー別、実績と予測、2019年～2024年、2024年～2029年、2034年
  • 病院
  • 専門クリニック
  • ホームケア
  • その他のエンドユーザー
  • 世界の視神経脊髄炎スペクトラム市場、アクアポリン-4（AQP4）抗体による視神経脊髄炎スペクトラム（NMOSD）のサブセグメンテーション（タイプ別）、実績と予測、2019年～2024年、2024年～2029年、2034年
  • AQP4-IgGを伴う再発性NMOSD
  • AQP4-IgGを伴う単相性NMOSD
  • AQP4-IgGを伴う重度の視神経炎
  • AQP4-IgGを伴う縦走性横断性脊髄炎（LETM）
  • 世界の視神経脊髄炎スペクトラム市場、アクアポリン4（AQP4）抗体なしの視神経脊髄炎スペクトラム（NMOSD）のサブセグメンテーション（タイプ別）、実績と予測、2019年～2024年、2024年～2029年、2034年
  • ミエリンオリゴデンドロサイト糖タンパク質（MOG）抗体（MOG-IgG）によるNMOSD
  • 血清陰性NMOSD
  • 特発性NMOSD症例
  • NMOSDは他の自己免疫疾患と関連している

第7章 地域別・国別分析

  • 世界の視神経脊髄炎スペクトラム市場：地域別、実績と予測、2019年～2024年、2024年～2029年、2034年
  • 世界の視神経脊髄炎スペクトラム市場：国別、実績と予測、2019年～2024年、2024年～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • 視神経脊髄炎スペクトラム市場：競合情勢
  • 視神経脊髄炎スペクトラム市場：企業プロファイル
    • F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
    • AstraZeneca Overview, Products and Services, Strategy and Financial Analysis
    • Merck KGaA Overview, Products and Services, Strategy and Financial Analysis
    • Laboratory Corporation of America Holding Overview, Products and Services, Strategy and Financial Analysis
    • Chugai Pharmaceutical Co. Ltd. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

  • Mayo Foundation for Medical Education and Research
  • Penn Medicine
  • Genentech Inc.
  • Oregon Health & Science University
  • Arup Laboratories
  • Argenx SE
  • TG Therapeutics Inc.
  • RemeGen Co. Ltd.
  • Metropolis Healthcare
  • IASO Biotherapeutics
  • Harbour BioMed
  • Rush University Medical Center
  • Bio-Thera Solutions Ltd.
  • Mitsubishi Tanabe Pharma Corporation
  • Viela Bio

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

  • 視神経脊髄炎スペクトラム市場2029年：新たな機会を提供する国
  • 視神経脊髄炎スペクトラム市場2029年：新たな機会を提供するセグメント
  • 視神経脊髄炎スペクトラム市場2029年：成長戦略
    • 市場動向に基づく戦略
    • 競合の戦略

第36章 付録

目次
Product Code: r34636

Neuromyelitis optica spectrum disorder (NMOSD) is a rare autoimmune disease that primarily affects the central nervous system, focusing on the spinal cord and optic nerves. The condition is characterized by severe inflammation and demyelination (damage to the protective sheath of nerve fibers) in these areas, leading to symptoms such as vision loss, paralysis, and sensory dysfunction.

The primary types of neuromyelitis optica spectrum disorder include NMOSD with aquaporin-4 antibodies and NMOSD without aquaporin-4 antibodies. NMOSD with aquaporin-4 antibodies occurs when the immune system mistakenly attacks nerve fibers, causing inflammation, vision impairment, and paralysis. Diagnosis is made through various methods, including imaging tests, magnetic resonance imaging (MRI), blood tests, and more. Treatment options include C5 protein inhibitors, monoclonal antibodies, plasma exchange therapy, corticosteroids, immunoglobulin therapy, medications, and others. These treatments are distributed through different channels, such as hospital pharmacies, retail pharmacies, and online pharmacies, and are used by a range of end-users, including hospitals, specialty clinics, and home care settings.

The neuromyelitis optica spectrum disorder market research report is one of a series of new reports from The Business Research Company that provides neuromyelitis optica spectrum disorder market statistics, including the neuromyelitis optica spectrum disorder industry global market size, regional shares, competitors with the neuromyelitis optica spectrum disorder market share, detailed neuromyelitis optica spectrum disorder market segments, market trends, and opportunities, and any further data you may need to thrive in the neuromyelitis optica spectrum disorder industry. This neuromyelitis optica spectrum disorder market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The neuromyelitis optica spectrum disorder market size has grown strongly in recent years. It will grow from $2.35 billion in 2024 to $2.55 billion in 2025 at a compound annual growth rate (CAGR) of 8.7%. The growth observed during the historical period can be attributed to factors such as the increasing prevalence of Neuromyelitis Optica Spectrum Disorder (NMOSD), greater awareness and early diagnosis, expanding therapeutic options and FDA approvals, growing research and development activities, and an increase in clinical trials for new therapies.

The neuromyelitis optica spectrum disorder market size is expected to see strong growth in the next few years. It will grow to $3.52 billion in 2029 at a compound annual growth rate (CAGR) of 8.4%. The growth in the forecast period is expected to be driven by rising awareness and early diagnosis, higher healthcare spending, increased investments in research and development, the growing prevalence of autoimmune diseases, more clinical trials for NMOSD therapies, and a rising demand for personalized medicine. Key trends for the forecast period include advancements in precision medicine, increased collaboration and partnerships, technological innovations, the integration of AI and big data in research, and a shift towards home-based treatments.

The rising prevalence of multiple sclerosis (MS) is expected to drive the growth of the neuromyelitis optica spectrum disorder (NMOSD) market. Multiple sclerosis is a chronic autoimmune disease that affects the central nervous system, causing inflammation, nerve damage, and neurological symptoms. The increasing prevalence of MS is attributed to improved diagnostic techniques, environmental factors, and genetic predisposition. Advancements in medical imaging, such as MRI, have enabled earlier and more accurate diagnoses, contributing to a rise in detected cases. As the number of MS diagnoses increases, there is greater awareness of neurological autoimmune diseases, which has led to improved diagnostic methods and a better understanding of conditions such as NMOSD. For example, in May 2024, the Multiple Sclerosis Trust reported that the UK sees around 7,100 new MS cases annually, with approximately 135 new diagnoses each week. Therefore, the growing prevalence of MS is fueling the growth of the NMOSD market.

Companies in the NMOSD market are focusing on developing innovative treatments, such as long-acting complement inhibitors, to enhance the effectiveness of therapies and improve patient outcomes. Long-acting complement inhibitors are designed to suppress the complement system for extended periods, preventing inflammation and nerve damage in NMOSD. These treatments help reduce relapses and contribute to long-term disease management. For instance, in March 2024, Alexion Pharmaceuticals, a U.S.-based biopharmaceutical company, and AstraZeneca, a UK-based pharmaceutical firm, received approval for ULTOMIRIS (ravulizumab-cwvz) for the treatment of adults with anti-aquaporin-4 (AQP4) antibody-positive NMOSD. ULTOMIRIS is the first and only long-acting C5 complement inhibitor approved for NMOSD treatment. The approval was based on the Phase III CHAMPION-NMOSD trial, which showed a 98.6% reduction in relapse risk over 73 weeks compared to a placebo, with no new safety concerns identified during the trial.

In October 2023, Amgen, a U.S.-based biotechnology company, acquired Horizon Therapeutics plc for $27.8 billion. This acquisition allows Amgen to expand its portfolio in rare and autoimmune diseases, strengthening its position in the NMOSD market with treatments such as UPLIZNA (ibalizumab-con) for adult patients who are anti-aquaporin-4 (AQP4) antibody-positive. Horizon Therapeutics, based in Ireland, specializes in treatments for NMOSD.

Major players in the neuromyelitis optica spectrum disorder market are F. Hoffmann-La Roche Ltd., AstraZeneca, Merck KGaA, Laboratory Corporation of America Holding, Chugai Pharmaceutical Co. Ltd., Mayo Foundation for Medical Education and Research, Penn Medicine, Genentech Inc., Oregon Health & Science University, Arup Laboratories, Argenx SE, TG Therapeutics Inc., RemeGen Co. Ltd., Metropolis Healthcare, IASO Biotherapeutics, Harbour BioMed, Rush University Medical Center, Bio-Thera Solutions Ltd., Mitsubishi Tanabe Pharma Corporation, Viela Bio, Opexa Therapeutics.

North America was the largest region in the neuromyelitis optica spectrum disorder market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in neuromyelitis optica spectrum disorder report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the neuromyelitis optica spectrum disorder market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The neuromyelitis optica spectrum disorder market consists of revenues earned by entities by providing services such as rehabilitation services, patient assistance programs, and intravenous immunoglobulin (IVIG) therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The neuromyelitis optica spectrum disorder market includes sales of immunosuppressants, corticosteroids, and symptomatic treatments. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Neuromyelitis Optica Spectrum Disorder Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on neuromyelitis optica spectrum disorder market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for neuromyelitis optica spectrum disorder ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The neuromyelitis optica spectrum disorder market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Type: Neuromyelitis Optica Spectrum Disorder With Aquaporin-4 Antibodies; Neuromyelitis Optica Spectrum Disorder Without Aquaporin-4 Antibodies
  • 2) By Diagnosis: Imaging Tests; Magnetic Resonance Imaging (MRI); Blood Tests; Others Diagnosis
  • 3) By Treatment Type: C5 Protein Inhibitor; Monoclonal Antibodies; Plasma Exchange Therapy; Corticosteroids; Immunoglobulin Therapy; Medication; Other Treatment Types
  • 4) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy
  • 5) By End-User: Hospitals; Specialty Clinics; Homecare; Other End-Users
  • Subsegments:
  • 1) By Neuromyelitis Optica Spectrum Disorder (NMOSD) With Aquaporin-4 (AQP4) Antibodies: Relapsing NMOSD with AQP4-IgG; Monophasic NMOSD with AQP4-IgG; Severe Optic Neuritis with AQP4-IgG; Longitudinally Extensive Transverse Myelitis (LETM) with AQP4-IgG
  • 2) By Neuromyelitis Optica Spectrum Disorder (NMOSD) Without Aquaporin-4 (AQP4) Antibodies: NMOSD with Myelin Oligodendrocyte Glycoprotein (MOG) Antibodies (MOG-IgG); Seronegative NMOSD; Idiopathic NMOSD Cases; NMOSD Associated With Other Autoimmune Disorders
  • Companies Mentioned: F. Hoffmann-La Roche Ltd.; AstraZeneca; Merck KGaA; Laboratory Corporation of America Holding; Chugai Pharmaceutical Co. Ltd.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Neuromyelitis Optica Spectrum Disorder Market Characteristics

3. Neuromyelitis Optica Spectrum Disorder Market Trends And Strategies

4. Neuromyelitis Optica Spectrum Disorder Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Neuromyelitis Optica Spectrum Disorder Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Neuromyelitis Optica Spectrum Disorder PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Neuromyelitis Optica Spectrum Disorder Market Growth Rate Analysis
  • 5.4. Global Neuromyelitis Optica Spectrum Disorder Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Neuromyelitis Optica Spectrum Disorder Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Neuromyelitis Optica Spectrum Disorder Total Addressable Market (TAM)

6. Neuromyelitis Optica Spectrum Disorder Market Segmentation

  • 6.1. Global Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Neuromyelitis Optica Spectrum Disorder With Aquaporin-4 Antibodies
  • Neuromyelitis Optica Spectrum Disorder Without Aquaporin-4 Antibodies
  • 6.2. Global Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Imaging Tests
  • Magnetic Resonance Imaging (MRI)
  • Blood Tests
  • Others Diagnosis
  • 6.3. Global Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • C5 Protein Inhibitor
  • Monoclonal Antibodies
  • Plasma Exchange Therapy
  • Corticosteroids
  • Immunoglobulin Therapy
  • Medication
  • Other Treatment Types
  • 6.4. Global Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • 6.5. Global Neuromyelitis Optica Spectrum Disorder Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hospitals
  • Specialty Clinics
  • Homecare
  • Other End-Users
  • 6.6. Global Neuromyelitis Optica Spectrum Disorder Market, Sub-Segmentation Of Neuromyelitis Optica Spectrum Disorder (NMOSD) With Aquaporin-4 (AQP4) Antibodies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Relapsing NMOSD with AQP4-IgG
  • Monophasic NMOSD with AQP4-IgG
  • Severe Optic Neuritis with AQP4-IgG
  • Longitudinally Extensive Transverse Myelitis (LETM) with AQP4-IgG
  • 6.7. Global Neuromyelitis Optica Spectrum Disorder Market, Sub-Segmentation Of Neuromyelitis Optica Spectrum Disorder (NMOSD) Without Aquaporin-4 (AQP4) Antibodies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • NMOSD with Myelin Oligodendrocyte Glycoprotein (MOG) Antibodies (MOG-IgG)
  • Seronegative NMOSD
  • Idiopathic NMOSD Cases
  • NMOSD Associated With Other Autoimmune Disorders

7. Neuromyelitis Optica Spectrum Disorder Market Regional And Country Analysis

  • 7.1. Global Neuromyelitis Optica Spectrum Disorder Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Neuromyelitis Optica Spectrum Disorder Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Neuromyelitis Optica Spectrum Disorder Market

  • 8.1. Asia-Pacific Neuromyelitis Optica Spectrum Disorder Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Neuromyelitis Optica Spectrum Disorder Market

  • 9.1. China Neuromyelitis Optica Spectrum Disorder Market Overview
  • 9.2. China Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Neuromyelitis Optica Spectrum Disorder Market

  • 10.1. India Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Neuromyelitis Optica Spectrum Disorder Market

  • 11.1. Japan Neuromyelitis Optica Spectrum Disorder Market Overview
  • 11.2. Japan Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Neuromyelitis Optica Spectrum Disorder Market

  • 12.1. Australia Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Neuromyelitis Optica Spectrum Disorder Market

  • 13.1. Indonesia Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Neuromyelitis Optica Spectrum Disorder Market

  • 14.1. South Korea Neuromyelitis Optica Spectrum Disorder Market Overview
  • 14.2. South Korea Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Neuromyelitis Optica Spectrum Disorder Market

  • 15.1. Western Europe Neuromyelitis Optica Spectrum Disorder Market Overview
  • 15.2. Western Europe Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Neuromyelitis Optica Spectrum Disorder Market

  • 16.1. UK Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Neuromyelitis Optica Spectrum Disorder Market

  • 17.1. Germany Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Neuromyelitis Optica Spectrum Disorder Market

  • 18.1. France Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Neuromyelitis Optica Spectrum Disorder Market

  • 19.1. Italy Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Neuromyelitis Optica Spectrum Disorder Market

  • 20.1. Spain Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Neuromyelitis Optica Spectrum Disorder Market

  • 21.1. Eastern Europe Neuromyelitis Optica Spectrum Disorder Market Overview
  • 21.2. Eastern Europe Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Neuromyelitis Optica Spectrum Disorder Market

  • 22.1. Russia Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Neuromyelitis Optica Spectrum Disorder Market

  • 23.1. North America Neuromyelitis Optica Spectrum Disorder Market Overview
  • 23.2. North America Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Neuromyelitis Optica Spectrum Disorder Market

  • 24.1. USA Neuromyelitis Optica Spectrum Disorder Market Overview
  • 24.2. USA Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Neuromyelitis Optica Spectrum Disorder Market

  • 25.1. Canada Neuromyelitis Optica Spectrum Disorder Market Overview
  • 25.2. Canada Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Neuromyelitis Optica Spectrum Disorder Market

  • 26.1. South America Neuromyelitis Optica Spectrum Disorder Market Overview
  • 26.2. South America Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Neuromyelitis Optica Spectrum Disorder Market

  • 27.1. Brazil Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Neuromyelitis Optica Spectrum Disorder Market

  • 28.1. Middle East Neuromyelitis Optica Spectrum Disorder Market Overview
  • 28.2. Middle East Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Neuromyelitis Optica Spectrum Disorder Market

  • 29.1. Africa Neuromyelitis Optica Spectrum Disorder Market Overview
  • 29.2. Africa Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Neuromyelitis Optica Spectrum Disorder Market Competitive Landscape And Company Profiles

  • 30.1. Neuromyelitis Optica Spectrum Disorder Market Competitive Landscape
  • 30.2. Neuromyelitis Optica Spectrum Disorder Market Company Profiles
    • 30.2.1. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. AstraZeneca Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. Merck KGaA Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. Laboratory Corporation of America Holding Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. Chugai Pharmaceutical Co. Ltd. Overview, Products and Services, Strategy and Financial Analysis

31. Neuromyelitis Optica Spectrum Disorder Market Other Major And Innovative Companies

  • 31.1. Mayo Foundation for Medical Education and Research
  • 31.2. Penn Medicine
  • 31.3. Genentech Inc.
  • 31.4. Oregon Health & Science University
  • 31.5. Arup Laboratories
  • 31.6. Argenx SE
  • 31.7. TG Therapeutics Inc.
  • 31.8. RemeGen Co. Ltd.
  • 31.9. Metropolis Healthcare
  • 31.10. IASO Biotherapeutics
  • 31.11. Harbour BioMed
  • 31.12. Rush University Medical Center
  • 31.13. Bio-Thera Solutions Ltd.
  • 31.14. Mitsubishi Tanabe Pharma Corporation
  • 31.15. Viela Bio

32. Global Neuromyelitis Optica Spectrum Disorder Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Neuromyelitis Optica Spectrum Disorder Market

34. Recent Developments In The Neuromyelitis Optica Spectrum Disorder Market

35. Neuromyelitis Optica Spectrum Disorder Market High Potential Countries, Segments and Strategies

  • 35.1 Neuromyelitis Optica Spectrum Disorder Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Neuromyelitis Optica Spectrum Disorder Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Neuromyelitis Optica Spectrum Disorder Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer